Article
Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
PloS one - 1 Jan 2012
Smith Robert A, Raugi Dana N, Pan Charlotte, Coyne Matthew, Hernandez Alexandra, Church Brad, Parker Kara, Mullins James I, Sow Papa Salif, Gottlieb Geoffrey S
Abstract excerpt
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a pressing need to identify new classes of antiretroviral agents that are active against HIV-2. Although recent data suggest that the integrase strand transfer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.